Overview Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism Status: Completed Trial end date: 2007-05-01 Target enrollment: Participant gender: Summary Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study. Phase: Phase 3 Details Lead Sponsor: Repros Therapeutics Inc.Treatments: Citric AcidClomipheneEnclomipheneSodium CitrateZuclomiphene